A day after National Pharmaceuticals Pricing Authority (NPPA) chairman Bhupendra Singh announced a further cut in stent prices, he said 61 percent of the stents distributed in India in 2017 were manufactured by domestic companies, up from 57 percent in 2016.
According to NPPA, imported brands, including those made by Abbott, Medtronic and Boston, made up for only 33 percent of the stents distributed in India in 2017.
Meanwhile, 7656 stents were manufactured in 2017 by China versus none in 2016, representing a 1-percent increase.
Ganesh Sabath, president of the Indian Stent Manufacturers Association, said that “what the NPPA did in 2017 was create a level playing field between multinational corporations and us. But we never imagined our share to grow to over 60 percent.”